What one share of Protagonist Therapeutics holds
Protagonist Therapeutics, Inc. (referred to as “Protagonist,” the “Company,” “we,” “our” or “us”) is an integrated discovery and development company with a validated technology platform. Our programs fall into three broad therapeutic areas: (i) inflammation and immunology (“I&I”), (ii) hematology and (iii) metabolic diseases.
Protagonist Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | $1.23 |
|---|---|
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | $1.94 |
| Cash and investments | $13.13 |
| Book value | $13.01 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2014 | — | −$49.38 | $1.32 | −$35.40 | — | −$55.55 |
| 2015 | — | −$59.32 | $1.59 | −$58.73 | — | −$100.58 |
| 2016 | — | −$5.80 | $0.05 | −$4.66 | — | — |
| 2017 | $1.13 | −$2.09 | $0.04 | $0.18 | — | $5.72 |
| 2018 | $1.38 | −$1.74 | $0.02 | −$2.25 | — | $4.85 |
| 2019 | — | −$2.98 | $0.04 | −$1.64 | — | $2.94 |
| 2020 | $0.83 | −$1.92 | $0.01 | −$2.12 | — | $6.39 |
| 2021 | $0.59 | −$2.71 | $0.02 | −$2.35 | — | $6.27 |
| 2022 | $0.54 | −$2.60 | $0.02 | −$2.22 | — | $4.37 |
| 2023 | $1.06 | −$1.39 | $0.01 | −$1.25 | — | $5.83 |
| 2024 | $6.68 | $4.23 | $0.02 | $2.81 | — | $11.06 |
| 2025 | $0.72 | −$2.05 | $0.03 | $0.88 | — | $9.82 |
Common questions about Protagonist Therapeutics
How much does one share of Protagonist Therapeutics earn?
Over the last 12 months, each share of Protagonist Therapeutics earned $1.23 of profit.
Does Protagonist Therapeutics pay a dividend?
Protagonist Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Protagonist Therapeutics’s book value per share?
Protagonist Therapeutics’s book value is $13.01 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Protagonist Therapeutics have?
Each share of Protagonist Therapeutics has $13.13 of cash and investments, as of June 30, 2026.
What is Protagonist Therapeutics’s free cash flow per share?
$1.94 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Protagonist Therapeutics bought back shares?
Protagonist Therapeutics’s share count rose about 27881% from 2014 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.